Application of a data continuity prediction algorithm to an electronic health record-based pharmacoepidemiology study

J Eval Clin Pract. 2024 Jun;30(4):716-725. doi: 10.1111/jep.14002. Epub 2024 May 2.

Abstract

Background and objectives: Use of algorithms to identify patients with high data-continuity in electronic health records (EHRs) may increase study validity. Practical experience with this approach remains limited.

Methods: We developed and validated four algorithms to identify patients with high data continuity in an EHR-based data source. Selected algorithms were then applied to a pharmacoepidemiologic study comparing rates of COVID-19 hospitalization in patients exposed to insulin versus noninsulin antidiabetic drugs.

Results: A model using a short list of five EHR-derived variables performed as well as more complex models to distinguish high- from low-data continuity patients. Higher data continuity was associated with more accurate ascertainment of key variables. In the pharmacoepidemiologic study, patients with higher data continuity had higher observed rates of the COVID-19 outcome and a large unadjusted association between insulin use and the outcome, but no association after propensity score adjustment.

Discussion: We found that a simple, portable algorithm to predict data continuity gave comparable performance to more complex methods. Use of the algorithm significantly impacted the results of an empirical study, with evidence of more valid results at higher levels of data continuity.

Keywords: COVID‐19; antidiabetic drugs; data continuity; diabetes; electronic health record; missing data.

MeSH terms

  • Adult
  • Aged
  • Algorithms*
  • COVID-19 / epidemiology
  • Electronic Health Records* / statistics & numerical data
  • Female
  • Hospitalization / statistics & numerical data
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Insulin / administration & dosage
  • Insulin / therapeutic use
  • Male
  • Middle Aged
  • Pharmacoepidemiology* / methods
  • SARS-CoV-2

Substances

  • Hypoglycemic Agents
  • Insulin